Results 261 to 270 of about 3,443,356 (396)

Inhibition of HMGA2 Leads to Reduced Cell Proliferation and Increased Apoptosis in Human Embryonal Carcinoma Cell Lines

Andrology, EarlyView.
ABSTRACT Background The most prevalent solid tumors in young men are testicular germ cell tumors (TGCTs), and embryonal carcinoma is the most common subtype among non‐seminomatous germ cell tumors (NSGCTs). Despite the excellent cure rates of cisplatin‐based chemotherapy, resistance develops in 15%–30% of patients with metastatic cancer, which results ...
Marco De Martino, Matteo Lampitto, Alfredo Fusco, Marco Barchi, Francesco Esposito, Paolo Chieffi   +5 more
wiley   +1 more source

Replication protein A protects lagging strand gaps, restricting PARP inhibitor-induced synthetic lethality in BRCA1-deficient tumors. [PDF]

Nucleic Acids Res
VanderVere-Carozza PS, Jordan MR, Garrett JE, Pollok KE, Pawelczak KS, Turchi JJ.   +5 more
europepmc   +1 more source

Supplementary Figure S1 from Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study [PDF]

Yvette Drew, Jae‐Weon Kim, Richard T. Penson, David M. O’Malley, Christine Parkinson, Patricia Roxburgh, Ruth Plummer, Seock‐Ah Im, Martina Imbimbo, Michelle Ferguson, Ora Rosengarten, Neeltje Steeghs, Min Hwan Kim, Einav Nili Gal‐Yam, Daliah Tsoref, Jae‐Hoon Kim, Benoît You, Maja J.A. de Jonge, Roy Lalisang, Eelke Gort, Sara Bastian, Kassondra Meyer, Laura Feeney, Nigel Baker, Mei-Lin Ah-See, Susan M. Domchek, Susana Banerjee   +26 more
openalex   +1 more source

Expanding the horizons of PARP inhibitors [PDF]

Nature Reviews Cancer, 2010
openaire   +2 more sources

Menopausal hormone therapy after ovarian cancer: A 10‐year survival analysis in premenopausal women

Acta Obstetricia et Gynecologica Scandinavica, EarlyView.
Among premenopausal women surgically treated for ovarian cancer, no difference in 10‐year overall survival was observed between postoperative MHT users and non‐users. Young ovarian cancer survivors should be recommended MHT after surgically induced menopause.
Åsa Ehlin von Kartaschew, Pernilla Dahm‐Kähler, Kenny Rodriguez Wallberg, Erik Holmberg, Angelique Flöter‐Rådestad   +4 more
wiley   +1 more source

Malignant craniopharyngiomas: Institutional experience and literature review

Brain Pathology, EarlyView.
We report the second case of malignant craniopharyngioma with BAP1 and TP53 mutations. A literature review identified 44 cases of malignant craniopharyngiomas with a median overall survival of 6 months. Eighteen (41%) occurred in patients without any history of radiation, suggesting that mechanisms other than radiation have contributed to their ...
Thomas J. Auen, Isabella W. Zhang, Weiwei Zhang, Jordan M. Burr, Matthew L. Carda, James L. Wisecarver, Nicole Shonka, Jesse L. Cox, Sahara J. Cathcart, Allison Cushman‐Vokoun, Jie Chen   +10 more
wiley   +1 more source

The mitochondrial translocation of phosphorylated EZH2 promotes PARP inhibitor resistance in BRCA1-deficient epithelial ovarian cancer. [PDF]

Cell Discov
Hu L, Ma X, Cai X, Yan T, Zhou K, Shan C, Guo N, Zheng H, Wang Y, Tong Y, Xie S, Zhang H, Chen C, Gong Z, Guo L, Lu R.   +15 more
europepmc   +1 more source

PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets [PDF]

, 2013
Girish M. Shah, Mihaela Robu, Nupur K. Purohit, Jyotika Rajawat, Lucio Tentori, Grazia Graziani   +5 more
openalex   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Characterization of exceptional responders with long-term PARP inhibitor therapy in recurrent ovarian cancer: an analysis of 23 patients from Charité. [PDF]

Arch Gynecol Obstet
Glajzer J, Sehouli J, Woopen H, Braicu EI, Baum J, Grabowski JP.   +5 more
europepmc   +1 more source